RIPK1 and amyotrophic lateral sclerosis: Concordantly, all of these reports revealed that RIPK1 is a major regulator of signaling pathways that lead to inflammation and regulated cell death, which is why RIPK1 has gained considerable interest as a drug target for treating a spectrum of human diseases, including amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, IBD, sepsis, viral infections, hepatitis, myocardial infarction, stroke, and IRI (reviewed in ref. [47] and our own data).